Status:
COMPLETED
Study of Epratuzumab in Systemic Lupus Erythematosus
Lead Sponsor:
UCB Pharma
Conditions:
Systemic Lupus Erythematosus
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Epratuzumab is an investigational antibody designed to help treat Systemic Lupus Erythematosus (SLE). The purpose of the study is to obtain additional long-term information regarding the safety and ef...
Detailed Description
Due to the logistical considerations, UCB has decided to consolidate the Phase II and Phase III open-label extension trials. Subjects completing this study will be offered the option of continuing to ...
Eligibility Criteria
Inclusion
- Must have participated in SL0003 or SL0004 and benefitted from participation in those studies
Exclusion
- Development of toxicity to epratuzumab
- Significant protocol deviations during the SL0003 or SL0004 studies
- Evidence of significant infection
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT00383513
Start Date
June 1 2006
End Date
January 1 2012
Last Update
July 12 2012
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States
2
Tucson, Arizona, United States
3
Los Angeles, California, United States
4
Upland, California, United States